Immersive technologies are becoming a reality in the OR. In Vivo explores the future of surgery, profiling innovators of augmented reality technologies and exploring the promise and challenges surrounding robotic surgery as companies try to take technologies to the next level.
The approval of several novel RNA therapeutics in the last five years and the success of the COVID-19 mRNA vaccines has revived interest in the potential of RNA-based therapies. DTx Pharma hopes to use fatty acid conjugation to improve the delivery and duration of small interfering RNA therapeutics for rare diseases.
Stuart Henderson, senior managing director and client lead for Accenture’s global life sciences practice, speaks to In Vivo about the emerging components of a winning biopharma development and portfolio strategy. CEOs are asking: “How do we change the cost of innovation?” says Henderson.
Cross-industry collaboration is the new focus of EU health care technology research funding activity. Under Horizon Europe, the Innovative Health Initiative will encourage convergence in health technology, and prioritize digital technologies and data analytics. No longer can EU-funded projects be pharma-only or medtech-only, said MedTech Europe’s Patrick Boisseau.
UK-based Immodulon Therapeutics is developing novel immunomodulators in the form of heat-killed bacteria, being trialed in combination with other cancer treatments such as checkpoint inhibitors. The biotech is initially looking at underserved areas, including pancreatic cancer.
Clinical-stage biopharma Starton Therapeutics is developing continuous delivery systems and transdermal technologies to improve the safety and efficacy of existing cancer medications, and eschewing VC firms in favor of retail investors. Chair and CEO Pedro Lichtinger recently appeared on Unicorn Hunters, an online reality TV show, to pitch the company to celebrity judges, and the public at large.
Funded by the UK government, The Rosalind Franklin Institute works with industrial and academic partners from across the UK to foster interdisciplinary research with “real impact.” Leaders from the growing institute talk to In Vivo about validating its success and what it means to seek truly ground-breaking innovation in 2021.
Despite accounting for 98% of our DNA, the ‘dark genome’ has yet to be effectively harnessed for drug discovery. Nucleome Therapeutics’ new modeling technology could finally provide the tools that have been missing, says CEO Danuta Jeziorska.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.